Newswise — (New York, NY – November 8, 2017)— Researchers at the Icahn School of Medicine at Mount Sinai have created the first mathematical model that can predict how a cancer patient will benefit from certain immunotherapies, according to a study published in Nature.
Scientists have long sought a way to discover whether patients will respond to new checkpoint inhibitor immunotherapies and to better understand the characteristics that indicate a tumor can be successfully treated with them. The proposed mathematical model, which captures aspects of the tumor’s evolution and the underlying interactions of the tumor with the immune system, is more accurate than previous genomic biomarkers in predicting how the tumor will respond to immunotherapy.
“We present an interdisciplinary approach to studying immunotherapy and immune surveillance of tumors,” said Benjamin Greenbaum, PhD, the senior author, who is affiliated with the departments of Medicine, Hematology and Medical Oncology, Pathology, and Oncological Sciences at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai. “This approach will hopefully lead to better mechanistic predictive modeling of response and future design of therapies that further take advantage of how the immune system recognizes tumors.”
This novel model also has the potential to help find new therapeutic targets within the immune system and to help design vaccines for patients who do not typically respond to immunotherapy.
To create this model, researchers used data from melanoma and lung cancer patients being treated with immune checkpoint inhibitors. The model tracked many properties within the immune response to the drugs, particularly neoantigens, which are specific to mutating and growing tumors.
Neoantigens have the potential to be prime immunotherapy targets, and the proposed framework will likely be useful in studies of acquired resistance to immunotherapy and may be crucial for understanding the circumstances in which immunotherapy causes autoimmune-like side effects.
The first author of the study is Marta Łuksza, PhD, a computer scientist from the Simons Center for Systems Biology at the Institute for Advanced Study. Dr. Greenbaum and Dr. Łuksza also played an integral role in a companion piece of research led by researchers Vinod P. Balachandran, MD, Taha Merghoub, PhD, and Steven D. Leach, MD, at Memorial Sloan Kettering Cancer Center (MSK) that was also published in Nature today. That study showed how a similar model can be used to understand immune response in patients with pancreatic cancer who survive longer than others. Both studies demonstrate that this is a likely path forward to understanding when the immune system will lead to productive recognition of a tumor.
“This research represents a big step forward in understanding why some tumors are more aggressive than others and being able to predict rationally which neoantigens will be the most effective at stimulating an immune response,” said Dr. Balachandran, a member of the David M. Rubenstein Center for Pancreatic Cancer Research at MSK, and corresponding author of the companion study in Nature.
This research was part of Stand Up To Cancer’s “Convergence” model funding, which brought together teams of scientists and clinicians from different fields and different institutions to figure out how to bring the benefits immunotherapy to more patients. It was supported by a Stand Up To Cancer–American Cancer Society Lung Cancer Dream Team Translational Research Grant (SU2C-AACR-DT17-15), a Stand Up To Cancer–National Science Foundation–Lustgarten Foundation Convergence Dream Team Grant, a Phillip A. Sharp Innovation in Collaboration Award from Stand Up To Cancer, the Janssen Research & Development LLC, the STARR Cancer Consortium, the Pershing Square Sohn Cancer Research Alliance, the NIH R01 CA205426, the V Foundation, the Lustgarten Foundation, the National Science Foundation (NSF) 1545935, the Swim Across America, Ludwig Institute for Cancer Research, the Parker Institute for Cancer Immunotherapy, the NCI K12 Paul Calabresi Career Development Award for Clinical Oncology K12CA184746-01A1. The work was also supported in part by the MSKCC Core Grant (P30 CA008748).
"It is extraordinary to see the Stand Up To Cancer 'Convergence' model, which integrates quantitative and clinical sciences, yield results like these. The potential benefit for patients diagnosed with melanoma or cancer of the lung or pancreas is exciting because these are some of the most challenging diagnoses for patients and their doctors and this research will help give patients the best information about the options they have," said Stand Up to Cancer President and CEO Sung Poblete, PhD, RN. "This research has tremendous value in predicting which patients may respond to immunotherapy before treatment begins, which will help us get the right medicine to the right patient. In addition the model provides new insights that will help researchers develop new immunotherapies for these cancers."
About the Mount Sinai Health System
The Mount Sinai Health System is New York City’s largest integrated delivery system encompassing seven hospital campuses, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai’s vision is to produce the safest care, the highest quality, the highest satisfaction, the best access and the best value of any health system in the nation. The System includes approximately 7,100 primary and specialty care physicians; 10 joint-venture ambulatory surgery centers; more than 140 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and 31 affiliated community health centers. Physicians are affiliated with the renowned Icahn School of Medicine at Mount Sinai, which is ranked among the highest in the nation in National Institutes of Health funding per investigator. The Mount Sinai Hospital is ranked No. 18 on U.S. News & World Report’s “Honor Roll” of top U.S. hospitals; it is one of the nation’s top 20 hospitals in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Geriatrics, Nephrology, and Neurology/Neurosurgery, and in the top 50 in four other specialties in the 2017-2018 “Best Hospitals” issue. Mount Sinai’s Kravis Children’s Hospital also is ranked in six out of ten pediatric specialties by U.S. News & World Report. The New York Eye and Ear Infirmary of Mount Sinai is ranked 12th nationally for Ophthalmology and 50th for Ear, Nose, and Throat, while Mount Sinai Beth Israel, Mount Sinai St. Luke’s and Mount Sinai West are ranked regionally. For more information, visit http://www.mountsinai.org/, or find Mount Sinai on Facebook, Twitter and YouTube.
RSS